CDNA Q1 Revenue +39% to $117.7M; Net Income $2.8M vs Loss
CareDx, Inc. reported a significant improvement in its first quarter 2026 financial results, achieving net income of $2.8 million, a substantial turnaround from a net loss of $10.4 million in Q1 2025. Total revenue increased by 39% to $117.7 million, driven primarily by strong growth in testing services and patient and digital solutions. The company also saw a positive shift in operating cash flow, providing $4.3 million compared to using $26.6 million in the prior year.
Key Highlights
- Total revenue increased 39% to $117.7 million in Q1 2026 from $84.7 million in Q1 2025.
- Net income was $2.8 million ($0.05 EPS) in Q1 2026, compared to a net loss of $10.4 million ($-0.19 EPS) in Q1 2025.
- Testing services revenue grew 47.6% to $91.4 million in Q1 2026.
- Patient and digital solutions revenue rose 33.5% to $16.0 million.
- Net cash provided by operating activities was $4.3 million in Q1 2026, a significant improvement from $26.6 million used in Q1 2025.
- Cash and cash equivalents increased to $77.9 million as of March 31, 2026, from $65.4 million at December 31, 2025.
- Litigation settlement expense decreased to $0.6 million in Q1 2026 from $5.4 million in Q1 2025.
- Company filed a petition for Supreme Court review regarding the Natera lawsuit on February 9, 2026.
Price Impact
More from CDNA
CareDx Stockholders Approve 1.6M Share Increase for Equity Plan
CDNA to Acquire Naveris for $160M; Q1 Revenue +39% to $118M; Raises FY26 Guidance
CDNA Sets 2026 Annual Meeting for June 11; Key Proposals Include Director Election, Equity Plan Amendment